Rilonacept Regeneron (previously Arcalyst) Uniunea Europeană - română - EMA (European Medicines Agency)

rilonacept regeneron (previously arcalyst)

regeneron uk limited - rilonacept - sindroamele periodice asociate criopirinei - imunosupresoare - rilonacept regeneron este indicat pentru tratamentul sindroamelor asociate cryopyrin periodice (capace) cu simptome severe, inclusiv sindrom auto-inflamatorii rece familiale (fcas) şi sindromul muckle-wells (dm), la adulţi şi copii cu vârsta de 12 ani şi mai vechi.

LIBTAYO 350 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

libtayo 350 mg

regeneron ireland designated activity company - irlanda - cemiplimabum - conc. pt. sol. perf. - 50mg/ml - anticorpi monoclonali

Libtayo Uniunea Europeană - română - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, celule scuamoase - agenți antineoplazici - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

REGENON 25 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

regenon 25 mg

temmler pharma gmbh - germania - amfepramonum - caps. moi - 25mg - medicamente pentru trat. obezitatii cu actiune centrala medicamente pentru trat. obezitatii cu actiune centrala

REGENON RETARD 60 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

regenon retard 60 mg

temmler pharma gmbh - germania - amfepramonum - caps. elib. prel. - 60mg - medicamente pentru trat. obezitatii cu actiune centrala medicamente pentru trat. obezitatii cu actiune centrala

BICALUTAMIDA ACCORD 50 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

bicalutamida accord 50 mg

accord healthcare limited - marea britanie - bicalutamidum - compr. film. - 50mg - antagonisti hormonali si substante inrudite antiandrogeni

BENDAMUSTINA ACCORD 2,5 mg/ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

bendamustina accord 2,5 mg/ml

accord healthcare limited - marea britanie - bendamustinum - pulb. pt. conc. pt. sol. perf. - 2,5mg/ml - agenti alchilanti analogi de nitrogen mustard